1-3 of 3
Jane R. Engler
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34 + cells

Brief Report
Jane R. Engler, Amity Frede, Verity Saunders, Andrew Zannettino, Deborah L. White, Timothy P. Hughes
Journal: Blood
Blood (2010) 116 (15): 2776–2778.
https://doi.org/10.1182/blood-2010-01-267013
Published: 2010
Journal Articles

OCT-1 Activity in CML CD34+ Cells Is Not Predictive of Molecular Response to Imatinib Treatment in CP-CML Patients, Despite the Strong Predictive Value of MNC OCT-1 Activity.

Jane R Engler, Amity Frede, Verity A Saunders, Andrew Christopher William Zannettino, BSc, PhD, Deborah L White, Timothy P. Hughes, MD
Journal: Blood
Blood (2009) 114 (22): 2189.
https://doi.org/10.1182/blood.V114.22.2189.2189
Published: 2009
Journal Articles

Reduced Activity of the OCT-1 Protein in Primitive CML Cells: A Likely Determinant of Stem Cell Resistance in Imatinib Treated CML Patients

Jane R Engler, Amity Frede, Andrew C W Zannettino, PhD, Deborah L White, PhD, Timothy P Hughes, MD
Journal: Blood
Blood (2008) 112 (11): 196.
https://doi.org/10.1182/blood.V112.11.196.196
Published: 2008